| Description | Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease and related diseases. |
| In vitro | Cinpanemab对聚集形态的α-syn表现出高度选择性，对纤维状重组α-syn的亲和力至少比单体重组α-syn高出800倍以上，且对人类帕金森病(PD)大脑组织[2]表现出强烈偏好。 |
| In vivo | Cinpanemab（30 mg/kg；腹腔注射）在接种α-syn PFFs[2]的小鼠模型中，能改善帕金森病（PD）样表型。 |
| Synonyms | BIIB054 |
| molecular weight | N/A |
| CAS | 2094516-02-4 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. 2. Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813. |